KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Interest & Investment Income (2019 - 2025)

Royalty Pharma's Interest & Investment Income history spans 7 years, with the latest figure at $7.1 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 21.76% year-over-year to $7.1 million; the TTM value through Dec 2025 reached $33.6 million, down 29.05%, while the annual FY2025 figure was $33.6 million, 29.05% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $7.1 million at Royalty Pharma, up from $6.9 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $43.9 million in Q4 2022 and bottomed at $6.5 million in Q4 2023.
  • The 5-year median for Interest & Investment Income is $11.8 million (2021), against an average of $14.3 million.
  • The largest annual shift saw Interest & Investment Income surged 672.59% in 2021 before it crashed 85.18% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $10.6 million in 2021, then skyrocketed by 312.19% to $43.9 million in 2022, then plummeted by 85.18% to $6.5 million in 2023, then soared by 39.03% to $9.0 million in 2024, then fell by 21.76% to $7.1 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Interest & Investment Income are $7.1 million (Q4 2025), $6.9 million (Q3 2025), and $8.3 million (Q2 2025).